Search details
1.
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
Nature
; 601(7893): 434-439, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34937944
2.
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Proc Natl Acad Sci U S A
; 120(30): e2221809120, 2023 07 25.
Article
in English
| MEDLINE | ID: mdl-37459541
3.
Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
Nature
; 629(8011): E9, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38649489
4.
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.
J Med Chem
; 67(9): 6938-6951, 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38687638
5.
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
bioRxiv
; 2024 May 24.
Article
in English
| MEDLINE | ID: mdl-38328238
6.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
bioRxiv
; 2024 May 23.
Article
in English
| MEDLINE | ID: mdl-38586029
7.
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
bioRxiv
; 2024 Mar 29.
Article
in English
| MEDLINE | ID: mdl-38464251
8.
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
bioRxiv
; 2024 Mar 21.
Article
in English
| MEDLINE | ID: mdl-38562774
9.
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.
Nat Commun
; 11(1): 2817, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32499547
Results
1 -
9
de 9
1
Next >
>>